Grifols (GRFS) Cash & Equivalents (2009 - 2025)
Grifols' (GRFS) quarterly Cash & Equivalents came in at $9.3 million in Q4 2025, down 99.11% YoY from $1.0 billion in Q4 2024, and down 99.11% on a QoQ basis from $1.0 billion in Q4 2024.
Grifols (GRFS) Cash & Equivalents (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Cash & Equivalents data on file, last reported at $9.3 million in Q4 2025.
- Quarterly Cash & Equivalents fell 99.11% year-over-year to $9.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (down 99.11% YoY) and the FY2025 annual result came in at $9.3 million, down 99.11% from the prior year.
- Cash & Equivalents eased to $9.3 million in Q4 2025, from $1.0 billion in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $3.1 billion in Q4 2021 to a low of $9.3 million in Q4 2025.
- A 5-year average of $1.0 billion and a median of $569.2 million in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2021 — Cash & Equivalents soared 342.97% — and 2025, when it plunged 99.11%.
- Tracing GRFS's Cash & Equivalents over 5 years: stood at $3.1 billion in 2021, then sank by 81.7% to $560.1 million in 2022, then grew by 1.62% to $569.2 million in 2023, then soared by 83.05% to $1.0 billion in 2024, then sank by 99.11% to $9.3 million in 2025.
- The last three Cash & Equivalents figures came in at $9.3 million (Q4 2025), $1.0 billion (Q4 2024), and $569.2 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 4.90 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 976.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 4.17 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 960.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.31 Mn |
| Dec 31, 2024 | 1.04 Bn |
| Dec 31, 2023 | 569.17 Mn |
| Dec 31, 2022 | 560.12 Mn |
| Dec 31, 2021 | 3.06 Bn |
| Dec 31, 2020 | 691.11 Mn |
| Sep 30, 2020 | 1.21 Bn |
| Mar 31, 2020 | 703.98 Mn |
| Dec 31, 2019 | 821.29 Mn |
| Sep 30, 2019 | 881.43 Mn |
| Mar 31, 2019 | 655.51 Mn |
| Dec 31, 2018 | 1.18 Bn |
| Sep 30, 2018 | 676.95 Mn |
| Jun 30, 2018 | 797.82 Mn |
| Mar 31, 2018 | 1.04 Bn |
| Dec 31, 2017 | 1.04 Bn |
| Jun 30, 2017 | 824.90 Mn |
| Dec 31, 2016 | 966.36 Mn |
| Sep 30, 2016 | 1.01 Bn |
| Jun 30, 2016 | 911.83 Mn |